ConCallIQ
Go Pro
INNOVACAPTAB Diversified 15 May 2026

Innova Captab Ltd — Q4 FY26

Innova Captab delivered a strong Q4 FY26 with revenue of INR 448 cr (+42% YoY) and full-year revenue of INR 1,630 cr (+31% YoY), driven by broad-based growth across CDMO (+24% to INR 1,133 cr) and branded generics (+51% to INR 497 cr).

bullish high
Compare with...
Revenue ₹448 Cr +31%
EBITDA ₹250 Cr +26.3%
PAT ₹38 Cr +10%
EBITDA Margin 15% -60bps
Duration 47 min
Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Innova Captab delivered a strong Q4 FY26 with revenue of INR 448 cr (+42% YoY) and full-year revenue of INR 1,630 cr (+31% YoY), driven by broad-based growth across CDMO (+24% to INR 1,133 cr) and branded generics (+51% to INR 497 cr). The Jammu facility contributed ~INR 300 cr in FY26 and is nearing breakeven, with management expecting margin expansion as utilization ramps. EBITDA margin for FY26 was 15.4%, down ~60bps YoY due to product mix, but management guided for EBITDA growth to outpace revenue growth in FY27. PAT grew 10% to INR 140.9 cr, with depreciation and interest costs largely fixed. Key risks include raw material price volatility from geopolitical tensions and potential margin pressure from new capex at Baddi. Overall, the company is well-positioned to sustain 20%+ revenue growth with improving profitability.

Risks4 trackedTranscriptfull text
Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Raw material price volatility

View Risks →
Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

CDMO Revenue (FY26) INR 1,133 cr
+24% YoY

CDMO segment grew driven by new customers and deeper wallet share.

Branded Generics Revenue (FY26) INR 497 cr
+51% YoY

Strong growth from geographical expansion and deeper penetration.

Jammu Facility Revenue (FY26) INR 300 cr
N/A (first full year)

Jammu facility nearing breakeven; expected to contribute positively in FY27.

Customer Base (CDMO) 350+
N/A

Expanded customer base to over 350 clients, including leading pharma companies.

Fast read

Guidance and risk preview

Top guidance 20%+ revenue growth in FY27

Management expects to maintain 20%+ revenue growth driven by capacity ramp-up, product portfolio expansion, and market penetration.

Top risk Raw material price volatility

Geopolitical tensions have led to an uptick in API and raw material prices, which could pressure margins if not fully passed on.

View Risks →